Thomas F. Gajewski to T-Lymphocytes
This is a "connection" page, showing publications Thomas F. Gajewski has written about T-Lymphocytes.
Connection Strength
7.373
-
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017 05 08; 31(5):711-723.e4.
Score: 0.365
-
Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment. Adv Exp Med Biol. 2017; 1036:19-31.
Score: 0.356
-
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc Natl Acad Sci U S A. 2016 11 29; 113(48):E7759-E7768.
Score: 0.353
-
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res. 2016 07; 4(7):563-8.
Score: 0.341
-
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy. Adv Immunol. 2016; 130:75-93.
Score: 0.334
-
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin Oncol. 2015 Aug; 42(4):663-71.
Score: 0.319
-
Melanoma-intrinsic ß-catenin signalling prevents anti-tumour immunity. Nature. 2015 Jul 09; 523(7559):231-5.
Score: 0.318
-
The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol. 2015 Apr; 36(4):250-6.
Score: 0.314
-
Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy. Mol Immunol. 2013 Oct; 55(3-4):283-91.
Score: 0.275
-
Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J Exp Med. 2012 Nov 19; 209(12):2157-63.
Score: 0.267
-
Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev. 2009 May; 229(1):126-44.
Score: 0.209
-
Molecular regulation of T-cell anergy. EMBO Rep. 2008 Jan; 9(1):50-5.
Score: 0.191
-
Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cells. J Immunol Methods. 2008 Feb 29; 331(1-2):94-102.
Score: 0.191
-
An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells. Cell Immunol. 2007 Jun; 247(2):95-102.
Score: 0.187
-
Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level. Blood. 2007 Sep 15; 110(6):1982-8.
Score: 0.183
-
Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006 Oct; 213:131-45.
Score: 0.175
-
Negative regulation of T-cell function by PD-1. Crit Rev Immunol. 2004; 24(4):229-37.
Score: 0.145
-
Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytes. Biochem Biophys Res Commun. 2003 Dec 19; 312(3):691-6.
Score: 0.144
-
T cell development and function in CrkL-deficient mice. Eur J Immunol. 2003 Oct; 33(10):2687-95.
Score: 0.142
-
CXCL9 and CXCL10 bring the heat to tumors. Sci Immunol. 2022 07 22; 7(73):eabq6509.
Score: 0.131
-
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. J Immunother Cancer. 2022 06; 10(6).
Score: 0.130
-
Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond. Clin Diagn Lab Immunol. 2000 Mar; 7(2):141-4.
Score: 0.111
-
Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-?-signaling mutant cancer cells. Nat Commun. 2020 01 30; 11(1):602.
Score: 0.110
-
Biochemical analysis of activated T lymphocytes. Protein phosphorylation and Ras, ERK, and JNK activation. Methods Mol Biol. 2000; 134:307-17.
Score: 0.110
-
B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J Exp Med. 1998 Jul 06; 188(1):205-10.
Score: 0.099
-
Back from the dead: TIL apoptosis in cancer immune evasion. Br J Cancer. 2018 02 06; 118(3):309-311.
Score: 0.096
-
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018 01 05; 359(6371):104-108.
Score: 0.096
-
Control of T lymphocyte signal transduction through clonal anergy. J Mol Med (Berl). 1996 Nov; 74(11):673-83.
Score: 0.088
-
Cutting Edge: Engineering Active IKKß in T Cells Drives Tumor Rejection. J Immunol. 2016 Apr 01; 196(7):2933-8.
Score: 0.084
-
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
Score: 0.083
-
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015 Nov 27; 350(6264):1084-9.
Score: 0.082
-
Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy. Cytokine. 2016 Jan; 77:245-7.
Score: 0.081
-
New perspectives on type I IFNs in cancer. Cytokine Growth Factor Rev. 2015 Apr; 26(2):175-8.
Score: 0.078
-
Therapeutic activity of high-dose intratumoral IFN-ß requires direct effect on the tumor vasculature. J Immunol. 2014 Oct 15; 193(8):4254-60.
Score: 0.076
-
Anergic T-lymphocyte clones have altered inositol phosphate, calcium, and tyrosine kinase signaling pathways. Proc Natl Acad Sci U S A. 1994 Jan 04; 91(1):38-42.
Score: 0.072
-
CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest. 2013 May; 123(5):1999-2010.
Score: 0.069
-
Cancer immunotherapy. Curr Opin Immunol. 2013 Apr; 25(2):259-60.
Score: 0.069
-
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). J Transl Med. 2012 Dec 10; 10:246.
Score: 0.067
-
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs. 2013 Jun; 31(3):769-73.
Score: 0.067
-
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol. 2011 Apr; 23(2):286-92.
Score: 0.059
-
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs. 2010 Dec; 11(12):1354-9.
Score: 0.058
-
Regulation of T-cell activation: differences among T-cell subsets. Immunol Rev. 1989 Oct; 111:79-110.
Score: 0.054
-
Protein kinase Ctheta focusing at the cSMAC is a consequence rather than cause of TCR signaling and is dependent on the MEK/ERK pathway. J Immunol. 2009 May 15; 182(10):6022-30.
Score: 0.052
-
Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5256-61.
Score: 0.047
-
Immune suppression in the tumor microenvironment. J Immunother. 2006 May-Jun; 29(3):233-40.
Score: 0.043
-
An adenoviral vector for probing promoter activity in primary immune cells. J Immunol Methods. 2006 Apr 20; 311(1-2):19-30.
Score: 0.042
-
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005 Apr; 54(4):307-14.
Score: 0.039
-
Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol. 2004 Jul; 15(7):1109-14.
Score: 0.037
-
Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol. 2003 Jun 15; 21(12):2342-8.
Score: 0.035
-
Integrating IL-12 into therapeutic cancer vaccines. Cancer Chemother Biol Response Modif. 2002; 20:343-9.
Score: 0.032
-
Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res. 2001 Mar; 7(3 Suppl):895s-901s.
Score: 0.030
-
Transplantation and the CD28/CTLA4/B7 pathway. Transplant Proc. 2001 Feb-Mar; 33(1-2):209-11.
Score: 0.030
-
Transgenic expression of the coxsackie/adenovirus receptor enables adenoviral-mediated gene delivery in naive T cells. Proc Natl Acad Sci U S A. 2000 Dec 05; 97(25):13784-9.
Score: 0.029
-
Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity. Mol Cancer Ther. 2018 11; 17(11):2399-2411.
Score: 0.025
-
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017 Nov 02; 171(4):934-949.e16.
Score: 0.024
-
The composition of the microbiota modulates allograft rejection. J Clin Invest. 2016 07 01; 126(7):2736-44.
Score: 0.021
-
Differential requirement for protein tyrosine kinase Fyn in the functional activation of antigen-specific T lymphocyte clones through the TCR or Thy-1. J Immunol. 1995 May 01; 154(9):4363-70.
Score: 0.020
-
Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer. 2015 Feb 01; 121(3):432-440.
Score: 0.019
-
A designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based library. Proc Natl Acad Sci U S A. 2009 Dec 29; 106(52):22211-6.
Score: 0.014
-
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer. Prostate. 2009 Feb 01; 69(2):142-8.
Score: 0.013
-
Nakahara memorial lecture. Regulation of T lymphocyte responses: interactions among receptors. Princess Takamatsu Symp. 1988; 19:15-27.
Score: 0.012
-
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol. 2007 Aug 01; 179(3):1960-8.
Score: 0.012
-
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Invest New Drugs. 2006 Mar; 24(2):141-9.
Score: 0.011
-
A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer. 2003 Feb; 39(2):191-6.
Score: 0.008